Federal Government advances plans for local vaccine manufacturing.

Federal Government advances plans for local vaccine manufacturing.

In its stride towards self-sufficiency in vaccine production, the federal government has undertaken a comprehensive review and validation of the National Plan for Vaccine Research & Development and Manufacturing in Nigeria. 

The move aligns with the Four Point Agenda health sector objectives of the Renewed Hope Agenda of the government, aiming to bolster local manufacturing and eliminate dependency on imported vaccines.

The National plan, a first of its kind in Africa, was initially developed in 2021 and delineates the roles of key stakeholders in Nigeria’s vaccine landscape. 

At a review and validation meeting organized by the National Institute for Pharmaceutical Research and Development (NIPRD) in Abuja over the weekend, the Minister of State for Health and Social Welfare, Dr. Tunji Alausa, expressed optimism about the tangible outcomes of the Government’s efforts in local vaccine production.

He said the efforts over the years to commence local vaccines production is already yielding the expected results.

According to him, the review and validation meeting provided critical stakeholders and policy-makers the opportunity to address critical healthcare issues, while noting that it will enhance Nigeria’s entry of the pharmaceutical sector into the larger African market.

Saying that the review and validation of the Draft Roadmap will fast-tract the achievement of the vaccine policy objectives of the federal government, Alausa, noted: “With this initiative, I am confident that the government prioritization as regards local vaccine production will begin to yield the desired result within the shortest possible time, and the reliance on importation of this important public health tool will be drastically reduced.

“The Federal Ministry of Health and Social Welfare will continue to provide the necessary oversight and work with NIPRD, partners and stakeholders at the various levels to ensure that the desired results of sustainable vaccine R&D and local production in Nigeria are achieved”.  

The minister who was represented by Dr. David Atuwo emphasized Government’s level of preparation to kick-start local vaccine manufacturing, saying, “Despite the various challenges militating against local production of vaccines, I want to state that appreciable progress has been achieved in these past few years.

“Nigeria has recently attained Maturity Level Three (ML3) for regulatory oversight and this includes the area of vaccines.

“With this and other ongoing reforms in the health sector, vaccines produced as a result of this process will not only satisfy national needs, but will also be available for international procurement.

“Whilst the government is taking steps to provide the needed infrastructure requisite for the implementation of local vaccines’ production, it is commendable that NIPRD, in line with its mandate, continues to set the pace for responsive innovation in this area.”

On the importance of the review and validation meeting, the Minister noted that “This high-level meeting is intended to bring together relevant stakeholders in order to synthesize ideas and solutions for a robust and contextual base plan to achieve sustainable local manufacturing of vaccines in Nigeria.

“This approach will provide a strong foundation that is underpinned by empirical evidence. The adoption of this bottom-up strategy in developing this plan ensures that innovative ideas embedded in this framework are designed to stimulate local vaccines R&D and vaccines production in Nigeria.”

In his remarks, NIPRD Director General (DG), Obi Adigwe, said the meeting was the first step to unlock the health value chain plan which will not only save lives but also address critical socio-economic indices such as job creation, capacity building, revenue generation and technology transfer.

He said: “Africa no longer has an interest in tokenistic interventions such as fill-finish products, but has become interested in building dependable, equitable, and veracious partnerships that will enable the Continent to undertake full R&D for the production of vaccines.”